Last reviewed · How we verify
Experimental Product
At a glance
| Generic name | Experimental Product |
|---|---|
| Also known as | Eczema Moisturizing Balm |
| Sponsor | Johnson & Johnson Consumer Inc. (J&JCI) |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC (EARLY_PHASE1)
- Clinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemia (PHASE2)
- A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients (PHASE1)
- Study of TGM-312-SC01 in Healthy Participants and Adults With MASH (PHASE1, PHASE2)
- Clinical Evaluation of an Experimental Remineralization Product (NA)
- MK-7075 (Miransertib) in Proteus Syndrome (PHASE2)
- Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) (PHASE1)
- This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Experimental Product CI brief — competitive landscape report
- Experimental Product updates RSS · CI watch RSS
- Johnson & Johnson Consumer Inc. (J&JCI) portfolio CI